New research reveals that individuals who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who halt traditional lifestyle plans.
Findings released in a major medical journal demonstrates that while obese individuals can lose substantial amounts of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users buying these drugs should be cognizant of the danger of fast rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to original weight within about a year and a half.
Comparing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, compared the outcomes of the injectable medications with other pills.
The team emphasize that individuals who lose weight through diet and exercise usually experience a less rapid creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Doctors propose the mechanism of the injections explains the accelerated weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, considering the significant potential of weight regain, the treatment is often long-term.
This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the persistent character of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Users who have stopped the jabs describe a powerful return of appetite.
"It felt as if something flipping and you're instantly ravenous," said an individual.
This challenge is worsened if patients have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Figures suggest that millions of adults in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, experts stress that while these medications are potent agents for weight loss, they are not a standalone fix and lasting health benefits relies on ongoing behavioural support.
